Deciphera Pharmaceuticals Inc (DCPH) Received its Third Buy in a Row

By Ryan Adsit

After Deutsche Bank and J.P. Morgan gave Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) a Buy rating last month, the company received another Buy, this time from Nomura. Analyst Christopher Marai maintained a Buy rating on Deciphera Pharmaceuticals Inc yesterday and set a price target of $57. The company’s shares closed last Monday at $35.90.

According to, Marai is a 4-star analyst with an average return of 6.9% and a 49.2% success rate. Marai covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Global Blood Therapeutics, and Voyager Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Deciphera Pharmaceuticals Inc with a $46.14 average price target, representing a 7.6% upside. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $55 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $42.99 and a one-year low of $18.55. Currently, Deciphera Pharmaceuticals Inc has an average volume of 433.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.